CYRX: Raising Price Target on CAR-T Opportunity – Zacks Small Cap Research (press release)
|
CYRX: Raising Price Target on CAR–T Opportunity
Zacks Small Cap Research (press release) In July an FDA advisory panel voted unanimously (10-0) to approve CTL019 (tisagenlecleucel-T), a novel CAR–T cell immunotherapy developed by Novartis, for the treatment of children and young adults (ages 3 – 25) with relapsed or refractory B-cell acute … |
